COVID-19
It does not require healthcare workers and first responders to conduct the test using personal protective equipment. Therefore, it should prevent the risk of transmitting the virus.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.
Traditional vaccine development and regulatory policies are changing in response to the current pandemic. Some of those approaches may become more common, expanding into other, non-pandemic-related areas in the future.
GlobalData released a report that showed the global healthcare sector has been subjected to an array of cyberattacks as it deals with the COVID-19 pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 20, 2020.
Swiss pharma giant Novartis will launch a Phase III trial assessing hydroxychloroquine for the treatment of COVID-19. The trial will be conducted across the United States.
The agency issued a statement saying that it will continue its activities, such as reviewing new drug applications and clinical trial, both COVID-19 and non-COVID-19, applications, “as we do everything possible to maintain continuity of operations in a very dynamic situation.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 17, 2020.
As Moderna moves forward with its mRNA vaccine candidate for COVID-19, the U.S. federal government is helping accelerate the potential medication with a $483 million infusion from the Biomedical Advanced Research and Development Authority.
Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease.
PRESS RELEASES